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Introduction Images Post-operative Course
• Cytochrome P450 enzymes are essential for the metabolism of many 
medications
• Genetic variability in these enzymes may influence a patient's response to 
commonly prescribed drug classes. CYP2D6 and CYP2C19 enzymes are part 
of the CYP450 enzyme
• CYP2D6: responsible for the metabolism of most of the commonly prescribed 
opiate medications
• CYP2C19: affects the metabolism of diazepam and carisoprodol, as well as 
clopidogrel, proton pump inhibitors, and several antidepressants
• Poor metabolizers of these enzymes are extremely rare and when deficiency 
present can cause severe and fatal side effects and overdose of drugs
• We herein report an unusual case of a poor metabolizer of medications 
metabolized by CYP2D6 and CYP2C19 enzymes due to genetic deficiency 
diagnosed on genetic testing
• Patient started complaining of intractable pain and due to lack of options in her 
case for pain control, Anesthesiology staff was called, who considering her 
known genetic deficiencies started her on intravenous (IV) ketamine infusion. 
Due to the complexity of her postoperative pain management and the risk of 
deleterious side effects, patient was admitted to the neurology intensive care unit 
(ICU).
• On POD (post op day) 1: Pain team was consulted who continued her on IV 
ketamine infusion. Her home medications for chronic pain and muscle spasms 
which included pregabalin and clonazepam were restarted.
• On POD 2: Methocarbamol was started which was then increased from 750 mg 
TID to 1 gm q6hr on POD 2. IV ketamine infusion was decreased to 
0.5mg/kg/hr on POD 2.
• On POD 3: Ketamine infusion was decreased to 0.25mg/kg/hr and IV 
acetaminophen 1G q 8 hrs. scheduled was started.
• On POD 4: Memantine 5 mg bid was started and ketamine infusion was later 
discontinued. IV acetaminophen was continued.
• On POD 5: Patient reported improvement in pain as ketamine was transitioned 
to memantine.
• On POD 6: Transferred to General Practice Unit (GPU) and was discharged 
home on POD 7. The whole process required a six day close management in 
ICU with pain service onboard to manage her intractable pain causing an 
unpleasant experience for the patient.
Clinical Vignette
Conclusion
• 56 year old female patient – PMHx of Ehlers-Danlos Syndrome (EDS) and  
known deficiency of CYP2D6 and CYP2C19
• Patient presented for an elective Occipital to T3 fusion
• The patient had a known deficiency of CYP2D6 and CYP2C19 diagnosed 
through genetic testing, the presenting deficiencies caused several instances of 
anaphylaxis, life threatening allergic reactions, serotonin syndrome and side 
effects including delirium to medications including morphine, hydromorphone, 
tramadol, codeine, diazepam, metoclopramide, ondansetron, amitriptyline, just 
to name a few
• On pre-operative visit patient did mention her concerns regarding post-
operative pain management because of extensive allergy list to several pain 
medications. Since patient also had history of difficult airway and failed 
intubation in past due to cervical surgeries, focus was done on airway and the 
presence of genetic deficiency somehow got ignored.
• A pre-operative planning for post-operative pain control was not formulated 
and pain team was not involved prior to surgery
• She underwent spinal surgery leading to a pain management dilemma starting 
in the recovery room
Figure 4: Metabolism of Sertraline in liver. 
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• This case represents an unusual presentation where a patient with Ehlers-
Danlos syndrome (EDS) has rare serious drug intolerance due to genetic 
deficiency of CYP2D6 and CYP2C19 enzymes
• When such patients are undergoing surgery, involving pain service early in 
the care can lead to a well formulated plan for postoperative pain 
management
• As seen in this case IV Ketamine is an excellent alternative medication for 
acute pain control when opioids can not be used due to the above 
mentioned genetic deficiencies as Ketamine’s major pathway is CYP3A4 
and CYP2B6 enzymes
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Table 1: Opioid Dosage and CYP Enzyme Deficiencies
Table 2: CYP2D6 is responsible for metabolism of most Opioids
Figure 3: Metabolism of Amitriptyline in liver. 
